Workflow Overview

Integrated Virtual Screening: Utilizing our proprietary datasets of approximately 4 billion small molecules and specialized peptide libraries, we identify promising candidates targeting the Aβ pathway. This extensive collection enables us to discover potential drug candidates, either as small molecules or peptides, with the ability to target AD in both individual and dual-action manners.​

​

Dual-Action Candidates 

Targeting Key Enzymes: We focus on discovering compounds capable of individually targeting crucial enzymes such as BACE1 and gamma-secretase or offering dual inhibition to block multiple pathological pathways simultaneously. This dual-action approach aims to enhance therapeutic efficacy and address the multifaceted nature of AD.​

 

Enhancement with non-canonical amino acids (NCAAs)

Innovative Peptide Design: For peptide-based hits, we incorporate NCAAs to improve peptide stability, bioavailability, and target affinity. This novel approach sets our peptide therapeutics apart from traditional methods, offering new standards in drug design.​

 

Computational and Machine Learning Edge

Advanced Tools: We leverage state-of-the-art computational resources and machine learning algorithms to refine hit selection, predict efficacy, and optimize lead compounds. This streamlines the drug discovery process, from identifying potential drugs to optimizing their structures for better efficacy, paving the way to preclinical readiness.​

 

Advancing Beyond Existing Aβ Pathway Inhibitors​

 

Pharmaeconomica's Approach

Dual-Action Strategy: Our strategy focuses on dual-action small molecules and peptides. Incorporating NCAAs into peptide leads represents a groundbreaking method to overcome traditional hurdles in peptide drug development, such as stability and efficacy.​

 

Data-Driven Design

Computational Precision: Our computational platform enables the rational design of compounds and peptides, including structure-activity relationship (SAR) studies. This ensures high specificity and potency against Aβ targets, relying on detailed analyses to create highly effective drugs.​

 

Preclinical Promise

Ready for Testing: We are advancing lead compounds with enhanced brain penetration and minimized toxicity, ready for rapid transition into preclinical testing. This approach promises significant advancements in AD treatment efficacy and safety, positioning our leads for preclinical success and beyond.

 

Our innovative methodologies and robust research infrastructure ensure that we are not just discovering theoretical molecules but are advancing viable candidates poised for preclinical success.